Aiobio was founded in 2011 and changed its name in 2017. It is an oral disease diagnostic device maker. Its core products are the Curae Cam and Curae Pen oral imaging devices, which use quantitative light-induced fluorescence (QLF) to assist in diagnosing dental caries.
The company positions QBLISS, an ecosystem combining devices, a platform and analytics for quantitative bio-fluorescence based diagnostics, as the center of its business model.
In May 2021, QLF-based caries testing received a National Health Insurance coverage notice, and in February 2025 coverage was extended to children aged 15 and under, with testing frequency raised to once every three months.
In Korea, revenue has grown as the company built a sales system through dental clinics and expanded promotion. Its LINKDENS oral care software began a domestic pilot service in June 2024 and is expanding into public health areas such as rural mobile dental clinic programs.
Overseas, the company exported Qscan Plus to GSK Consumer Healthcare (now Haleon) in 2019 and obtained U.S. FDA Class II market clearance in September 2024. The U.S. sales base was restructured in fiscal 2025 into a 100%-owned subsidiary through a capital injection.
In competitive terms, the company presents its reimbursed QLF method as a differentiator for entry into the formal healthcare system. Founder and CEO Yoon Hong-cheol held 36.65% of issued shares as of June 30, 2025.